Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 18, 2009 - Issue 4
Submit an article Journal homepage
132
Views
11
CrossRef citations to date
0
Altmetric
Drug Evaluations

The role of telavancin in the treatment of MRSA infections in hospital

Matteo Bassetti University of Genoa School of Medicine, S. Martino Hospital, Clinica Malattie Infettive, Infectious Diseases Division, A.O.U. San Martino, L.go R.Benzi 10, 16132 Genova, Italy +0039 010 5555132; +0039 010 3537680; [email protected]
, MD PhD,
Malgorzata Mikulska University of Genoa School of Medicine, S. Martino Hospital, Clinica Malattie Infettive, Infectious Diseases Division, A.O.U. San Martino, L.go R.Benzi 10, 16132 Genova, Italy +0039 010 5555132; +0039 010 3537680; [email protected]
,
Elda Righi University of Genoa School of Medicine, S. Martino Hospital, Clinica Malattie Infettive, Infectious Diseases Division, A.O.U. San Martino, L.go R.Benzi 10, 16132 Genova, Italy +0039 010 5555132; +0039 010 3537680; [email protected]
,
Laura Nicolini University of Genoa School of Medicine, S. Martino Hospital, Clinica Malattie Infettive, Infectious Diseases Division, A.O.U. San Martino, L.go R.Benzi 10, 16132 Genova, Italy +0039 010 5555132; +0039 010 3537680; [email protected]
&
Claudio Viscoli University of Genoa School of Medicine, S. Martino Hospital, Clinica Malattie Infettive, Infectious Diseases Division, A.O.U. San Martino, L.go R.Benzi 10, 16132 Genova, Italy +0039 010 5555132; +0039 010 3537680; [email protected]
Pages 521-529 | Published online: 01 Apr 2009

Bibliography

  • Hegde SS, Reyes N, Skinner R, Difuntorum S. Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus. J Antimicrob Chemother2008;61(1):169-72
  • Madrigal AG, Basuino L, Chambers HF. Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother2005;49(8):3163-5
  • Reyes N, Skinner R, Benton BM, et al. Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother2006;58(2):462-5
  • Reyes N, Skinner R, Kaniga K, et al. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother2005;49(10):4344-6
  • Yin LY, Calhoun JH, Thomas TS, Wirtz ED. Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model. J Antimicrob Chemother2009;63(2):357-60
  • Miro JM, Garcia-de-la-Maria C, Armero Y, et al. Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother2007;51(7):2373-7
  • Staphylococcus aureus resistant to vancomycin–United States, 2002. MMWR Morb Mortal Wkly Rep2002;51(26):565-7
  • Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis2004;38(4):521-8
  • Leadbetter MR, Adams SM, Bazzini B, et al. Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J Antibiot (Tokyo)2004;57(5):326-36
  • Leuthner KD, Cheung CM, Rybak MJ. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother2006;58(2):338-43
  • King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against gram-positive bacteria. J Antimicrob Chemother2004;53(5):797-803
  • Pace JL, Krause K, Johnston D, et al. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother2003;47(11):3602-4
  • Saravolatz LD, Pawlak J, Johnson LB. Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother2007;60(2):406-9
  • Stryjewski ME, Chu VH, O'Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother2006;50(3):862-7
  • Hatano K, Matsuzaki K, Sato Y, et al. In vitro antimicrobial activity of telavancin against methicillin-resistant Staphylococcus aureus clinical isolates from Japan 2006. J Antibiot (Tokyo)2007;60(11):709-12
  • Krause KM, Renelli M, Difuntorum S, et al. In vitro activity of telavancin against resistant gram-positive bacteria. Antimicrob Agents Chemother2008;52(7):2647-52
  • Draghi DC, Benton BM, Krause KM, et al. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. J Antimicrob Chemother2008;62(1):116-21
  • Draghi DC, Benton BM, Krause KM, et al. Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States. Antimicrob Agents Chemother2008;52(7):2383-8
  • Jansen WT, Verel A, Verhoef J, Milatovic D. In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe. Antimicrob Agents Chemother2007;51(9):3420-4
  • Bae IG, Stryjewski ME, Lalani T, et al. Associations between patient outcome and bacterial genotype of S. aureus isolates from a multinational trial of hospital-acquired pneumonia. [abstract K-493]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Washington, DC, October 25-28 2008
  • Lapalnte KL, Mermel LA. In vitro Activity of Telavancin (TEL) & Vancomycin (VAN) against biofilm-producing Staphylococcus aureus (SA), S. epidermidis (SE) & Enterococcus faecalis (EF). [abstract F1-362]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Washington, DC, October 25-28 2008
  • Baquero F. Pneumococcal resistance to beta-lactam antibiotics: a global geographic overview. Microb Drug Resist1995;1(2):115-20
  • Hiramatsu K. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am J Med1998;104(5A):7S-10S
  • McCormick AW, Whitney CG, Farley MM, et al. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med2003;9(4):424-30
  • Goldstein EJ, Citron DM, Merriam CV, et al. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp. Antimicrob Agents Chemother2004;48(6):2149-52
  • Shaw JP, Seroogy J, Kaniga K, et al. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother2005;49(1):195-201
  • Shaw JP, McCullough J, Jaw Tsai S. Protein binding of 14C telavancin in plasma and human skin blister fluid. [abstract A-1878]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Washington, DC, October 25-28 2008
  • Duchin K, Shaw J, Spencer E, et al. Single dose pharmacokinetics (PK) of telavancin (TLV) in subjects with renal dysfunction. [abstract P-1028]. 14th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); Prague, Czech Republic, May 1-4, 2004
  • Duchin K, Shaw J, Spencer E, et al. Single dose pharmacokinetics (PK) of telavancin (TLV) in healthy elderly subjects. [abstract P-1027]. 14th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); Prague, Czech Republic, May 1-4, 2004
  • Wong SL, Shaw JP, Barriere S, et al. Pharmacokinetics of intravenous telavancin in subjects with hepatic impairment. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); San Francisco, CA, September 17-20 2006
  • Sun HK, Duchin K, Nightingale CH, et al. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob Agents Chemother2006;50(2):788-90
  • Gotfried MH, Shaw JP, Benton BM, et al. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob Agents Chemother2008;52(1):92-7
  • Lodise TP Jr, Gotfried M, Barriere S, Drusano GL. Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother2008;52(7):2300-4
  • Hegde SS, Reyes N, Wiens T, et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother2004;48(8):3043-50
  • Odenholt I, Lowdin E, Cars O. Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model. Antimicrob Agents Chemother2007;51(9):3311-6
  • Bowker KE, Noel AR, Tomaselli SG, Macgowan AP. Pharmacodynamics of Telavancin: relationship of AUC/MIC to antibacterial effect and emergence of resistance. [abstract A-980]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Washington, DC, October 25-28 2008
  • Gander S, Kinnaird A, Finch R. Telavancin: in vitro activity against staphylococci in a biofilm model. J Antimicrob Chemother2005;56(2):337-43
  • Barcia-Macay M, Lemaire S, Mingeot-Leclercq MP, et al. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother2006;58(6):1177-84
  • Barcia-Macay M, Mouaden F, Mingeot-Leclercq MP, et al. Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic fibroblasts). J Antimicrob Chemother2008;61(6):1288-94
  • Stryjewski ME, O'Riordan WD, Lau WK, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis2005;40(11):1601-7
  • Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis2008;46(11):1683-93
  • Wilson SE, O'Riordan W, Hopkins A, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures. Am J Surg2008. [Epub ahead of print] doi:10.1016/j.amjsurg.2008.05.012
  • Dunbar L, Sibley D, Hunt J, et al. Recurrence of skin infections in patients treated with telavancin versus vancomycin for complicated skin and soft tissue infections in a New Orleans emergency department. In: Care C, editor. 28th International Symposium on Intensive Care and Emergency Medicine. Brussels, Belgium: P29 (doi: 10.1186/cc6250), 2008
  • Rubinstein E, Corey GR, Stryjewski ME, et al. Telavancin for hospital-acquired pneumonia, including ventilator-associated pneumonia: the ATTAIN studies. [abstract 075]. 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); Spain, Barcelona, April 19-22 2008
  • Rubinstein E, Corey GR, Stryjewski ME, et al. Telavancin for Treatment of Hospital-Acquired Pneumonia (HAP) Caused by MRSA and MSSA: the ATTAIN studies. [abstract K-530]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Washington, DC, October 25-28 2008
  • Rubinstein E, Corey GR, Boucher HW, et al. Telavancin for the treatment of hospital-acquired pneumonia in severely Ill and older patients: the ATTAIN studies. [abstract k-529]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Washington, DC, October 25-28 2008
  • Barriere S, Genter F, Spencer E, et al. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol2004;44(7):689-95

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.